Track-HD - Track-HD

eids Universitair Medisch Centrum0 个研究点目标入组 90 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Ability to tolerate MRI and sample donation;• Subjects will be either:
•1. Control subject
•a. Partner/spouse of a patient, not at risk of HD
•b. Known non-carriers for HD (after genetic testing);2. Premanifest gene carrier
•a. Positive genetic test with CAG repeat length >= 40 and
•b. Burden of pathology score [(CAG-35.5) × age] >250 and
•c. Absence of diagnostic motor features according to the UHDRS 99;3. Early HD
•a. Positive genetic test with CAG repeat length >= 40 and
•b. Presence of diagnostic motor features according to the UHDRS 99 and
•c. Shoulson and Fahn stage 1 (TFC > 9-13) or 2 (TFC >= 7) according to the UHDRS 99 - functional capacity

•Stage 3 (TFC <= 6) or greater at time of enrolment
•Less than 18 years of age
•More than 65 years of age
•Major psychiatric disorder at time of enrolment
•Concomitant significant neurological disorder
•Concomitant significant medical illness
•Unsuitability for MRI, e.g. claustrophobia, metal implants
•Unwillingness to donate blood
•History of significant head injury
•Drug and/or alcohol abuse
•Significant hand injuries that preclude either writing or rapid computerized responding
•Currently participating in a clinical drug trial

发起方